Palmitic Acid-Conjugated GnRH Derivative for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GnRH sustained-release products cause pain and tissue injury due to high doses required for prolonged drug release, with biodegradable polymers not fully absorbed, leading to residual lumps and inflammation, and have issues with initial drug release and stability.
Innovation Solution
A long-acting palmitic acid-conjugated GnRH derivative is developed, increasing the in vivo half-life and bioavailability by conjugating palmitic acid to GnRH, which is then formulated into a pharmaceutical composition for improved efficacy and ease of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If high doses of GnRH are used to achieve prolonged therapeutic effect, then the duration of action is improved, but pain and tissue injury at injection site increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of GnRH through conjugation with palmitic acid and conversion to salt forms (sodium or acetate salts). This structural modification fundamentally changes the pharmacokinetic parameters of the drug, extending its half-life from minutes to days while enabling sustained release at lower doses, thereby resolving the contradiction between duration of action and injection site harm
Solution Approach 2:
The invention creates a composite molecular structure by conjugating palmitic acid (a fatty acid) with the GnRH peptide. This composite structure combines the therapeutic properties of GnRH with the prolonged circulation characteristics of fatty acid conjugates, achieving extended duration of action without requiring high doses that cause injection site pain and tissue injury
2Duration of action of moving object
If additional sustained release ingredients are added to extend drug release time, then the duration of action is improved, but the total dose and formulation complexity increase
Solution Approach 1:
The patent extracts and eliminates the need for additional sustained release ingredients by incorporating the sustained release functionality directly into the GnRH molecule itself through palmitic acid conjugation. This removes the separate sustained release component, simplifying the overall formulation while maintaining extended drug release time
Solution Approach 2:
The invention merges the therapeutic agent (GnRH) with the sustained release mechanism (palmitic acid conjugate) into a single integrated molecular entity. This combination eliminates the need for separate sustained release ingredients and complex formulation designs, achieving prolonged drug release through the inherent properties of the conjugated structure
3Duration of action of moving object
If biodegradable polymers are used for sustained release, then the duration of action is improved, but residual lumps and inflammation occur due to incomplete absorption
Solution Approach 1:
The patent replaces long-lasting biodegradable polymers that leave residual lumps with a smaller molecular weight palmitic acid conjugate that is completely metabolizable. The conjugate acts as a temporary carrier that fulfills its sustained release function and then is fully broken down and eliminated by the body, avoiding persistent residues and associated inflammation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The palmitic acid-conjugated GnRH derivative maintains high blood levels for a prolonged period, reducing dosing frequency, minimizing adverse effects like pain and residual lump formation, and enhancing therapeutic effects on sex hormone-dependent diseases.
Implementation Method 1
a long-acting palmitic acid-conjugated GnRH derivative was prepared by conjugating palmitic acid to a GnRH derivative which is designed to have an increased in vivo half-life of GnRH
Implementation Method 2
the long-acting palmitic acid-conjugated GnRH derivative was found to exhibit excellent bioavailability and a prolonged in vivo half-life and maintain a high blood level
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a novel long-acting palmitic acid-conjugated gonadotrophin-releasing hormone (GnRH) derivative and a pharmaceutical composition containing the same. A GnRH derivative of the present invention is expected to greatly contribute, through excellent bioavailability and increased half-life in blood, to the reduction in drug dosing frequency and dosage and the like in the treatment of sex hormone-dependent diseases. Particularly, the GnRH derivative can overcome the disadvantages of existing GnRH sustained-release preparations, which have the side effects of residual feeling and pain at the injection site.